TSY-0210 is a well-known antibiotic with a focused, but potent antibacterial spectrum that addresses nearly half of the priority pathogens identified by the World Health Organization (WHO). Formosa Pharmaceuticals possesses a novel manufacturing process that provides robust yields with enhanced purity compared to the marketed product, which has sales in limited regions. Together with AimMax Therapeutics, Formosa Pharmaceuticals is positioning TSY-0210 for novel disease applications. Additionally, due to its low water solubility, TSY-0210 is a prime candidate for the APNT nanotechnology platform and may be studied accordingly to improve dissolution and physicochemical properties.